Biomedical measurand type.
1Reasons for interindividual variation in steady-state serum phosphorus concentrations are largely unknown.
2These associations may explain the link between serum phosphorus levels and CVD events.
3In addition, the patient had low to low-normal serum phosphorus with high urine phosphorus.
4The high phosphate diet did not affect serum phosphorus concentration.
5The calcimimetic cinacalcet reduces both serum calcium and PTH levels and raises serum phosphorus.
6Factors determining serum phosphorus concentration are largely unknown.
7A higher serum phosphorus level is associated with cardiovascular disease (CVD) events among community-living populations.
8However, regardless of the dietary phosphate contents, serum phosphorus levels were consistently elevated in Galnt3 knockout mice.
9There was no statistically significant association between urine DA, serum phosphorus, FGF-23 or PTH in adjusted models.
10The total amount of phosphate binders prescribed was adjusted to maintain the serum phosphorus at normal levels.
11Intact FGF23 correlated with serum phosphorus.
12The Ca x PO4 product, however, showed a mortality risk trend similar to that seen with serum phosphorus alone.
13Logistic regression analysis is then used to describe the demographic, comorbid, and laboratory parameters associated with high serum phosphorus.
14Dietary intakes of phosphorus and phosphorus-rich foods were associated only weakly with circulating serum phosphorus concentrations, if at all.
15On the basis of this evidence, clinical practice guidelines recommend specific targets for serum phosphorus levels in the dialysis population.
16Background: Phosphate binders are widely used to control serum phosphorus levels in patients with chronic kidney disease (CKD).